Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666263 · ClinicalTrials.gov registry record · Phase 3
Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy
A Phase 3 study, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
NCT00666263 is a Phase 3 study that has completed, run by Baxalta now part of Shire. The registered enrollment target is 50 participants.
The verdict
NCT00666263, a Phase 3 study, has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy (effect on grip strength and disability) and safety/tolerability of IGIV, 10% in subjects with Multifocal Motor Neuropathy.
Interventions
- BIOLOGICAL Immune Globulin Intravenous (human), 10%
- BIOLOGICAL 0.25% human albumin solution (Placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2008-08-22 |
| Est. Completion | 2011-08-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00666263
The ClinicalTrials.gov registry entry for NCT00666263 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxalta now part of Shire, which has 74 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Immune Globulin Intravenous (human), 10% is the first listed.
NCT00666263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00666263 about?
NCT00666263 is a clinical study titled "Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy". The purpose of the study is to evaluate the efficacy (effect on grip strength and disability) and safety/tolerability of IGIV, 10% in subjects with Multifocal Motor Neuropathy.
What is the current status of trial NCT00666263?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2008-08-22. Estimated completion is 2011-08-11.
What interventions are being tested in trial NCT00666263?
The interventions under investigation include: Immune Globulin Intravenous (human), 10% (BIOLOGICAL), 0.25% human albumin solution (Placebo) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00666263?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.